Employing a slash-and-burn technique to streamline its pipeline, Vical Inc. said it is not completing its Phase III low-dose trial of Allovectin-7 in metastatic melanoma due to the improbability of it achieving desired endpoints, is closing a Phase II trial of Allovectin-7 for early stage head and neck cancer, and would no longer develop Leuvectin for prostate or kidney cancer. (BioWorld Today)
Employing a slash-and-burn technique to streamline its pipeline, Vical Inc. said it is not completing its Phase III low-dose trial of Allovectin-7 in metastatic melanoma due to the improbability of it achieving desired endpoints, is closing a Phase II trial of Allovectin-7 for early stage head and neck cancer, and would no longer develop Leuvectin for prostate or kidney cancer. (BioWorld Today)
When trying to get a drug approved, biotechnology companies must provide the FDA with data - data showing that a drug is efficacious, that it works in the appropriate patient and that it is safe, among other things. (BioWorld Today)
When trying to get a drug approved, biotechnology companies must provide the FDA with data - data showing that a drug is efficacious, that it works in the appropriate patient and that it is safe, among other things. (BioWorld Today)
